
Original release date: April 21, 2020
Access to this course expires on: March 4, 2023 at 11:59 PM Pacific Time
CME .5
Faculty: Ashley Cimino-Mathews, MD
Learning Objectives:
- Describe the use of IHC in classification of metastases to the breast or a cancer of unknown primary
- Understand the use of PD-L1 IHC as an emerging biomarker in triple negative breast cancer